Engineers at the University of California San Diego have developed neutrophil “nanosponges” that can safely absorb and neutralize a variety of proteins that play a role in the progression of rheumatoid arthritis. Injections of these nanosponges effectively treated severe rheumatoid arthritis in two mouse models. Administering the nanosponges early on also prevented the disease from developing.
The work is published Sept. 3 in Nature Nanotechnology.
“Nanosponges are a new paradigm of treatment to block pathological molecules from triggering disease in the body,” said senior author Liangfang Zhang, a nanoengineering professor at the UC San Diego Jacobs School of Engineering. “Rather than creating treatments to block a few specific types of pathological molecules, we are developing a platform that can block a broad spectrum of them, and this way we can treat and prevent disease more effectively and efficiently.”
This work is one of the latest examples of therapeutic nanosponges developed by Zhang’s lab. Zhang, who is also affiliated with the Institute of Engineering in Medicine and Moores Cancer Center at UC San Diego, and his team previously developed red blood cell nanosponges to combat and prevent MRSA infections and macrophage nanosponges to treat and manage sepsis.
The new nanosponges are nanoparticles of biodegradable polymer coated with the cell membranes of neutrophils, a type of white blood cell.
Neutrophils are among the immune system’s first responders against invading pathogens. They are also known to play a role in the development of rheumatoid arthritis, a chronic autoimmune disease that causes painful inflammation in the joints and can ultimately lead to damage of cartilage and bone tissue.
When rheumatoid arthritis develops, cells in the joints produce inflammatory proteins called cytokines. Release of cytokines signals neutrophils to enter the joints. Once there, cytokines bind to receptors on the neutrophil surfaces, activating them to release more cytokines, which in turn draws more neutrophils to the joints and so on.
The nanosponges essentially nip this inflammatory cascade in the bud. By acting as tiny neutrophil decoys, they intercept cytokines and stop them from signaling even more neutrophils to the joints, reducing inflammation and joint damage.
These nanosponges offer a promising alternative to current treatments for rheumatoid arthritis. Some monoclonal antibody drugs, for example, have helped patients manage symptoms of the disease, but they work by neutralizing only specific types of cytokines. This is not sufficient to treat the disease, said Zhang, because there are so many different types of cytokines and pathological molecules involved.
“Neutralizing just one or two types might not be as effective. So our approach is to take neutrophil cell membranes, which naturally have receptors to bind all these different types of cytokines, and use them to manage an entire population of inflammatory molecules,” said Zhang.
“This strategy removes the need to identify specific cytokines or inflammatory signals in the process. Using entire neutrophil cell membranes, we’re cutting off all these inflammatory signals at once,” said first author Qiangzhe Zhang, a Ph.D. student in Professor Liangfang Zhang’s research group at UC San Diego.
To make the neutrophil nanosponges, the researchers first developed a method to separate neutrophils from whole blood. They then processed the cells in a solution that causes them to swell and burst, leaving the membranes behind. The membranes were then broken up into much smaller pieces. Mixing them with ball-shaped nanoparticles made of biodegradable polymer fused the neutrophil cell membranes onto the nanoparticle surfaces.
“One of the major challenges of this work was streamlining this entire process, from isolating neutrophils from blood to removing the membranes, and making this process repeatable. We spent a lot of time figuring this out and eventually created a consistent neutrophil nanosponge production line,” said Qiangzhe Zhang.
In mouse models of severe rheumatoid arthritis, injecting nanosponges in inflamed joints led to reduced swelling and protected cartilage from further damage. The nanosponges performed just as well as treatments in which mice were administered a high dose of monoclonal antibodies.
The nanosponges also worked as a preventive treatment when administered prior to inducing the disease in another group of mice.
Professor Liangfang Zhang cautions that the nanosponge treatment does not eliminate the disease. “We are basically able to manage the disease. It’s not completely gone. But swelling is greatly reduced and cartilage damage is minimized,” he said.
The team hopes to one day see their work in clinical trials.
The Latest on: Rheumatoid arthritis
via Google News
The Latest on: Reumatoid arthritis
- New Research Among People Living With Rheumatoid Arthritis Reveals Key Determinants Of Patient Satisfaction With Doctorson March 20, 2020 at 9:57 am
/PRNewswire/ -- MyHealthTeams, creator of the largest and fastest-growing social networks for people facing chronic health conditions, today unveiled ...
- Arthritis drug answer to pregnancy malaria, study findson March 20, 2020 at 7:16 am
The new study, published in Science Advances, found that the drug Anakinra restored fetal growth and reduced deaths in an experimental model. Anakinra is commonly used to treat rheumatoid arthritis ...
- Drugs for Rheumatoid Arthritis Market Research Report 2020: Global Market Size By Players, Regions, Type, Application Forecast To 2026on March 19, 2020 at 10:32 pm
Drugs for Rheumatoid Arthritis Market” 2020-2026 describes a detailed evaluation and proficient study on the current and future state of the Drugs for Rheumatoid Arthritis market across the globe, ...
- Genentech arthritis drug to be tested against COVID-19on March 19, 2020 at 12:19 pm
Biotech giant Genentech Inc. is working with federal agencies to start a late-stage clinical trial in early April of its already-approved rheumatoid arthritis drug Actemra against the virus that ...
- Regeneron to treat coronavirus patients this week in trial using its rheumatoid arthritis drugon March 18, 2020 at 5:28 pm
"This could in a very short time give hope to the most critical people," Regeneron Chief Scientific Officer Dr. George Yancopoulos told CNBC.
- Rheumatoid Arthritis Drugs Market To Reach USD 36.11 Billion By 2027on March 18, 2020 at 6:46 am
The Global Rheumatoid Arthritis Drugs Market is forecast to reach USD 36.11 Billion by 2027, according to a new report by Reports and Data. Rheumatoid arthritis is an inflammatory disease that affects ...
- Visiongain Report: Global Rheumatoid Arthritis Drugs Market Estimated to Grow at a CAGR of 0.6% in the Second Half of the Forecast Periodon March 18, 2020 at 3:00 am
/PRNewswire/ -- The global Rheumatoid Arthritis market is estimated to have reached $58bn in 2018 and is expected to grow at a CAGR of 0.6% in the second ...
- Sanofi, Regeneron begin testing arthritis drug as coronavirus treatmenton March 16, 2020 at 5:13 am
(Reuters) - Sanofi SA and partner Regeneron Pharmaceuticals Inc have started a clinical trial of their rheumatoid arthritis drug Kevzara as a treatment for the coronavirus, the companies said on ...
- Living with Rheumatoid Arthritison March 12, 2020 at 5:13 am
A physical therapist or sports medicine specialist may be able to offer advice to patients who wish to participate in a sport or physical activity but require modifications or assistive devices ...
- Identification of highly potent and selective inhibitor, TIPTP, of the p22phox-Rubicon axis as a therapeutic agent for rheumatoid arthritison March 12, 2020 at 3:08 am
LPS (Escherichia coli O111:B4) and ATP were purchased from Sigma. Specific antibodies against Rubicon (ab92388) were purchased from Abcam. Antibodies against Beclin-1 (3738) and UVRAG (5320) were ...
via Bing News